This company has been marked as potentially delisted and may not be actively trading. NASDAQ:HUMAW Humacyte (HUMAW) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisNews and Trends About Humacyte Stock (NASDAQ:HUMAW) Get Humacyte alerts:Sign Up Key Stats Today's Range$0.0009▼$0.000950-Day Range N/A52-Week Range$0.00▼$0.40VolumeN/AAverage Volume22,203 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Humacyte, Inc. is a biotechnology company developing implantable, bioengineered human tissues for use in vascular repair and other medical applications. Its primary technology is the human acellular vessel (HAV), a tissue-engineered vascular graft designed to provide a durable alternative to synthetic grafts and donated blood vessels. Humacyte’s HAV platform is being studied for potential use in vascular trauma, arteriovenous access for hemodialysis, peripheral arterial disease, and coronary artery bypass procedures. The company’s products are investigational unless specifically approved by regulators for a particular use, and its development programs are subject to clinical and regulatory review. Humacyte was founded by biomedical engineer and physician Laura Niklason, who serves as the company’s chief executive officer and has led the development of its regenerative-medicine platform. The company is based in Durham, North Carolina, and its clinical development activities are conducted through research and medical collaborations in the United States and other regions.AI Generated. May Contain Errors. Read More Receive HUMAW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HUMAW Stock News HeadlinesHumacyte (HUMA)September 23, 2026 | es.investing.comHumacyte Gets US FDA Clearance to Extend Symvess Shelf Life to 36 MonthsSeptember 9, 2026 | finance.yahoo.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.October 3 at 1:00 AM | Banyan Hill Publishing (Ad)Humacyte, Inc: Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 MonthsSeptember 9, 2026 | finanznachrichten.deHumacyte's Symvess Shelf Life Extended To 36 Months Following FDA AuthorizationSeptember 9, 2026 | rttnews.comHumacyte (HUMA) Q2 2026 Earnings Call TranscriptAugust 19, 2026 | finance.yahoo.comHumacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026August 7, 2026 | markets.businessinsider.comHumacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual ...June 15, 2026 | markets.businessinsider.comSee More Headlines Company Calendar Today10/03/2026Next Earnings (Estimated)11/06/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:HUMAW CIK1818382 Webwww.humacyte.com Phone919-313-9633FaxN/AEmployees150Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$2.12 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:HUMAW) was last updated on 10/3/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HUMAW Stock Alerts